Cytokinetics’ (CYTK) Buy Rating Reiterated at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a report released on Wednesday,Benzinga reports. Needham & Company LLC currently has a $72.00 target price on the biopharmaceutical company’s stock. CYTK has been the topic of several other research reports. Evercore ISI upgraded Cytokinetics to a “strong-buy” […]
Needham & Company LLC reaffirmed their buy rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a report released on Wednesday,Benzinga reports. Needham & Company LLC currently has a $72.00 target price on the biopharmaceutical company’s stock. CYTK has been the topic of several other research reports. Evercore ISI upgraded Cytokinetics to a “strong-buy” […]
